ClinicalTrials.gg
CompletedNCT00644709Updated Feb 18, 2021

A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)

A Phase 4 interventional study of Atorvastatin in Dyslipidemias, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 15 sites in Belgium. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
196
Allocation
Non-randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 47 studies testing atorvastatin in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Dyslipidemias.

Enrollment
22nd of 47
196 · median 165
Started
2003
with 5 others
Phase 4
22 of 47
1 open now
Registered
14th of 47
by date
Lead sponsor
9 of 47
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 47 studies testing atorvastatin in Dyslipidemias, this one is the 22nd largest by enrollment, is one of 6 that started in 2003, is one of 22 in phase 4, and was the 14th registered.

Dyslipidemias

1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 47 studies testing atorvastatin in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing atorvastatin in Dyslipidemias, or all of them as a file.
02

Study summary

A study of the long-term (1 year) effectiveness of atorvastatin to keep patients of high cardiovascular risk at the LDL cholesterol goal of \<115 mg/dL

03

Conditions studied

  • Dyslipidemias

Browse trials for

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of base study
  • Dyslipidemia and at high risk of CHD

Exclusion criteria

Exclusion Criteria:

  • Impaired liver function
  • Gastrointestinal disease that could limit drug absorption
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    Arm A

    Drug: Atorvastatin

Interventions

  • Atorvastatin tablets at starting doses of 10, 20, 40, or 80 mg once daily. Three dose adjustments were allowed at baseline, Week 17, and Week 34. Patients who did not meet the LDL-C target at any of these time points had their doses doubled except for those who were on the 80 mg dose. Treatment was given for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Achievement of low-density lipoprotein cholesterol (LDL-C) target of <115 mg/dL

    Time frame: Week 52

Secondary outcomes

  1. Achievement of LDL-C target and total cholesterol target (<190 mg/dL) concomitantly

    Time frame: Week 52

  2. LDL-C, high-density lipoprotein cholesterol (HDL-C), total cholesterol, and triglyceride levels

    Time frame: Baseline and Week 6 for base study; Baseline and Weeks 17, 34, and 52 for extension study

  3. Percent change from baseline of base study in LDL-C, HDL-C, non-HDL-C (triglycerides of >200 mg/dL), total cholesterol, and triglycerides in patients who were statin-naive at baseline of base study

    Time frame: Baseline and Weeks 17, 34, and 52

  4. Achievement of LDL-C target grouped according to whether patients had achieved target at the start of this extension study

    Time frame: Week 52

  5. Adverse events and laboratory test changes

    Time frame: Weeks 17, 34, and 52

  6. Achievement of LDL-C target

    Time frame: Weeks 17 and 34

  7. Achievement of LDL-C target by diabetic patients

    Time frame: Week 52

07

Study locations

15 sites
  • Pfizer Investigational Site
    Antwerpen, 2018, Belgium
  • Pfizer Investigational Site
    Brasschaat, 2930, Belgium
  • Pfizer Investigational Site
    Brussels, 1180, Belgium
  • Pfizer Investigational Site
    Genk, B-3600, Belgium
  • Pfizer Investigational Site
    Gent, 9000, Belgium
  • Pfizer Investigational Site
    Gilly (charleroi), 6060, Belgium
  • Pfizer Investigational Site
    La Louvière, 7100, Belgium
  • Pfizer Investigational Site
    Mechelen, 2800, Belgium
  • Pfizer Investigational Site
    Menen, 8930, Belgium
  • Pfizer Investigational Site
    Merksem, 2170, Belgium
  • Pfizer Investigational Site
    Mortsel, 2640, Belgium
  • Pfizer Investigational Site
    Roeselare, 8800, Belgium
  • Pfizer Investigational Site
    Seraing, 4100, Belgium
  • Pfizer Investigational Site
    Wilrijk, 2610, Belgium
  • Pfizer Investigational Site
    Wingene, 8750, Belgium
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2008
First posted
Mar 27, 2008
Start
Sep 2003
CompletionActual
Mar 2005
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00644709
Responsible party
Sponsor
First posted
Mar 27, 2008
Start date
Sep 2003
Completion
Mar 2005
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion